According to Greg Brockman on X, citing user IterIntellectus, an Australian technologist reportedly sequenced his rescue dog's tumor DNA for about $3,000, used ChatGPT and AlphaFold to identify mutated proteins and match drug targets, and designed a custom mRNA cancer vaccine that coincided with a halving of the tumor after the first injection (source: Greg Brockman; original account: IterIntellectus). As reported by Greg Brockman, a genomics professor described the effort as gobsmacking and questioned why similar personalized pipelines are not being rolled out to humans, highlighting potential AGI-enabled drug discovery workflows and rapid translational timelines if regulatory pathways are addressed (source: Greg Brockman). According to the X thread, the reported workflow included DNA sequencing, variant prioritization, neoantigen selection, and mRNA construct design, suggesting a low-cost, consumer-accessible stack that could compress discovery cycles and expand precision oncology opportunities for small labs, startups, and veterinary oncology providers (source: IterIntellectus via Greg Brockman).

According to Satya Nadella, new research published in Cell demonstrates how the AI platform GigaTIME enables simulation of spatial proteomics from routine pathology slides, allowing for large-scale analysis of tumor microenvironments across numerous cancer types and subtypes (Source: Satya Nadella, Twitter, Dec 9, 2025). Developed in collaboration with Providence and the University of Washington, GigaTIME is designed to help scientists rapidly transition from raw data to actionable insights. This innovation facilitates the identification of connections between genetic mutations, immune responses, and clinical outcomes, offering significant opportunities for AI-driven advancements in oncology research and healthcare. The ability to leverage population-scale spatial data with AI stands to accelerate biomarker discovery, enhance personalized medicine, and improve treatment strategies for cancer patients (Source: Cell, Dec 2025).